Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma

NCT00216437 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

FED

Sponsor class

Stopped lack of accrual

Conditions

Cancer of Liver

Interventions

DRUG: Capecitabine (Xeloda)

Sponsor

James A. Haley Veterans Administration Hospital

Collaborators

[object Object]